Table 3

Trials of neoadjuvant chemoradiation followed by surgery in oesophageal cancer

Trial	Treatment arm(s)	No of patients	Histology and stage	No complete resections/No operations	Path CR rate	Survival (median unless otherwise stated)
*Statistically significant difference.
NR, not reported; RT, radiotherapy; 5-FU, 5-fluorouracil; CR, complete response.
Poplin²²³	Cisplatin/5-FU/RT	113	Squamous stage I–III	32/71	16%	12 months
Forastiere²²⁴	Cisplatin/vinblastine/5-FU/RT	43	Squamous and adeno stage I–III	36/41	23%	>26 months
Gray²²⁵	Paclitaxel/ Carboplatin/5-FU/RT	73	Squamous and adeno stage I–III	56/59	54%	24 months
Stahl²²⁶	Cisplatin/5-FU/leucovorin/RT	25	Squamous and adeno stage II–III	16/19	40%	>16 months
Nygaard²¹⁸	Cisplatin/ bleomycin	50	Squamous stage I–II	NR	NR	8 months
	RT	48				11months
	Cisplatin/bleomycin/RT	47				9 months
	Surgery alone	41				8 months
Le Prise²¹⁹	Cisplatin/5-FU/RT	41	Squamous stage I–II	35/35	10%	10 months
	Surgery alone	45		38/42	—	10.5 months
Bosset²²¹	Cisplatin/RT	143	Squamous stage I–II	112/138	21%	18.6 months
	Surgery alone	139		94/137*	—	18.6 months
Walsh²²⁰	Cisplatin/5-FU/RT	58	Adeno stage I–III	NR	25%	16 months
	Surgery alone	55			—	11 months*
Urba²²²	Cisplatin/vinblatine/5-FU/RT	50	Squamous and adeno stage I–II	NR	28%	32% 3 year
	Surgery alone	50		NR	—	15% 3 year*